908 Devices (NASDAQ:MASS) Issues Earnings Results, Beats Expectations By $0.03 EPS

908 Devices (NASDAQ:MASS) released its quarterly earnings results on Tuesday. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.03, Zacks reports. 908 Devices had a negative net margin of 62.40% and a negative return on equity of 14.03%. The firm had revenue of $16.07 million for the quarter, compared to the consensus estimate of $15.37 million.

Here are the key takeaways from 908 Devices’ conference call:

• Second-quarter revenue rose 23% year over year to $16.1 million, while 198 devices were shipped and the installed base reached 4,101. U.S. state and local customers contributed more than half of quarterly revenue, supported by demand for modernized detection equipment.
• Profitability improved meaningfully, with adjusted EBITDA loss narrowing to $1.9 million from $3.9 million a year earlier and adjusted gross margin expanding to 57%. Management raised the low end of full-year 2026 revenue guidance to $68 million-$70 million, or 21%-25% growth.
• The NIRLab acquisition is gaining early traction, with more than 35 devices sold in roughly two months, each including a multiyear software subscription. Management sees cross-selling potential with MX908 and other products and aspires to increase recurring revenue from its current 31% of total revenue toward 40% over time.
• The AVCAD military program remains unresolved after its current contract ended, with the government evaluating both a continued development path and commercially available products. The company excluded AVCAD from 2026 guidance, although any contribution would be upside and management continues to view it as a potential $10 million-plus long-term opportunity.
• The company ended the quarter with $101.5 million in cash and no debt, but consumed $10.2 million during the quarter, including $13.5 million for the NIRLab acquisition. Management continues to target a mid-single-digit-million adjusted EBITDA loss for 2026 rather than breakeven.

908 Devices Stock Performance

Shares of 908 Devices stock traded down $0.37 during trading on Wednesday, reaching $9.64. The company had a trading volume of 312,999 shares, compared to its average volume of 308,424. 908 Devices has a fifty-two week low of $5.03 and a fifty-two week high of $10.52. The firm’s fifty day moving average is $8.23 and its 200-day moving average is $7.34. The company has a market cap of $364.53 million, a price-to-earnings ratio of -9.64 and a beta of 0.66.

908 Devices News Roundup

Here are the key news stories impacting 908 Devices this week:

• Positive Sentiment: Q2 results exceeded expectations. 908 Devices reported revenue of $16.07 million, up 23% year over year and above the $15.37 million consensus estimate. Its adjusted loss of $0.11 per share was narrower than the expected $0.14 loss and improved from a $0.18 loss a year earlier. 908 Devices Reports Second Quarter 2026 Financial Results and Raises Low End of 2026 Revenue Outlook
• Positive Sentiment: Management raised the low end of its 2026 revenue outlook. The company now expects full-year revenue of $68 million to $70 million, compared with the prior outlook’s lower end and broadly in line with the $68.6 million analyst consensus. The forecast excludes potential revenue from AVCAD, leaving possible upside if that business contributes. 908 Devices signals 2026 revenue outlook while excluding AVCAD from core guidance
• Positive Sentiment: Profitability trends improved. The company said its adjusted EBITDA loss narrowed by more than half from the prior year, while executives struck an upbeat tone on growth momentum during the earnings call. 908 Devices Inc. Earnings Call Highlights Growth Momentum
• Neutral Sentiment: 908 Devices plans to present at the 17th Annual Midwest IDEAS Investor Conference. The event could provide additional visibility into demand, guidance and the company’s growth strategy, but it does not itself change financial estimates. 908 Devices to Present at the 17th Annual Midwest IDEAS Investor Conference
• Negative Sentiment: 908 Devices remains unprofitable. The company continues to report a substantial net loss, with a negative net margin of 62.4%, and analysts still expect a full-year loss. This may limit enthusiasm even after the revenue and guidance improvements. 908 Devices Reports Q2 Loss, Tops Revenue Estimates

Analyst Ratings Changes

MASS has been the topic of a number of analyst reports. Stifel Nicolaus set a $12.00 target price on 908 Devices in a research report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of 908 Devices in a report on Friday. Roth Capital restated a “buy” rating on shares of 908 Devices in a research note on Wednesday. Finally, Wall Street Zen downgraded 908 Devices from a “buy” rating to a “hold” rating in a report on Saturday, July 18th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, 908 Devices currently has an average rating of “Hold” and an average target price of $11.50.

Insider Activity

In other 908 Devices news, Director Christopher D. Brown sold 20,000 shares of 908 Devices stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $8.49, for a total value of $169,800.00. Following the completion of the transaction, the director directly owned 823,359 shares in the company, valued at $6,990,317.91. The trade was a 2.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Joseph H. Iv Griffith sold 6,940 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $9.03, for a total transaction of $62,668.20. Following the transaction, the chief financial officer directly owned 132,956 shares of the company’s stock, valued at approximately $1,200,592.68. This trade represents a 4.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 89,140 shares of company stock valued at $787,308. 28.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On 908 Devices

Several hedge funds and other institutional investors have recently made changes to their positions in the business. State of Wisconsin Investment Board acquired a new stake in 908 Devices in the 4th quarter valued at approximately $170,000. Graham Capital Management L.P. boosted its position in 908 Devices by 12.9% during the 4th quarter. Graham Capital Management L.P. now owns 20,787 shares of the company’s stock worth $109,000 after acquiring an additional 2,374 shares during the period. Wells Fargo & Company MN grew its stake in shares of 908 Devices by 72.1% in the fourth quarter. Wells Fargo & Company MN now owns 30,623 shares of the company’s stock worth $161,000 after purchasing an additional 12,828 shares in the last quarter. Deutsche Bank AG grew its stake in shares of 908 Devices by 3,351.1% in the fourth quarter. Deutsche Bank AG now owns 18,429 shares of the company’s stock worth $97,000 after purchasing an additional 17,895 shares in the last quarter. Finally, Brevan Howard Capital Management LP acquired a new position in shares of 908 Devices during the third quarter valued at $102,000. 88.06% of the stock is currently owned by institutional investors and hedge funds.

About 908 Devices

908 Devices Inc (NASDAQ: MASS) is a developer and manufacturer of portable analytical instruments designed to deliver rapid chemical detection in field and laboratory environments. The company’s core focus lies in miniaturizing high-performance mass spectrometry and ion mobility spectrometry technologies, enabling users to perform on-site analysis that traditionally required benchtop equipment.

Key products in 908 Devices’ portfolio include the MX908, a handheld high-resolution mass spectrometer capable of detecting and identifying a broad range of chemicals and explosives; the M908 portable mass spectrometer for laboratory or mobile units; and the ZipChip capillary electrophoresis system for high-throughput, microfluidic separations.